“Rising Focus on Gene Therapy and Precision Medicine”
- One prominent trend in the retinitis pigmentosa (RP) market is the increasing adoption of gene therapy and precision medicine approaches
- The growing recognition of RP as a genetically heterogeneous disorder has led to a surge in research focused on targeted, mutation-specific treatment strategies
- For instance, Spark Therapeutics' Luxturna (voretigene neparvovec), approved by the FDA, is the first gene therapy for an inherited retinal disease, offering long-term vision improvement in patients with RPE65 mutations
- This trend is transforming the RP treatment paradigm by shifting the focus from symptomatic relief to root-cause intervention, promising durable therapeutic benefits
- As more gene therapies progress through clinical trials and gain regulatory approval, the market is expected to grow substantially, especially in regions with advanced genomic infrastructure
- Overall, this trend supports a move toward earlier intervention, personalized treatment plans, and improved patient outcomes in RP care
